Nuklearmedizin 2020; 59(02): 144
DOI: 10.1055/s-0040-1708294
Wissenschaftliche Poster
PET, SPECT & Co. I
© Georg Thieme Verlag KG Stuttgart · New York

Quantification of Iodine-123-mIBG SPECT/CT using CZT and NaI detectors: feasibility in neuroblastoma

J Rogasch
1   Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Nuklearmedizin, Berlin
,
S Bluemel
1   Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Nuklearmedizin, Berlin
,
F Buch
1   Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Nuklearmedizin, Berlin
,
S Spreckelmeyer
1   Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Nuklearmedizin, Berlin
,
A Eggert
2   Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Pädiatrie m.S. Onkologie und Hämatologie, Berlin
,
H Amthauer
1   Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Nuklearmedizin, Berlin
,
I Schatka
1   Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Klinik für Nuklearmedizin, Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2020 (online)

 

Ziel/Aim In Iodine-123-mIBG SPECT/CT for neuroblastoma (NB), the feasibility and potential of lesion uptake quantification for therapy monitoring remain unclear. We sought to evaluate normal organ and lesion SUV acquired with either a NaI or CZT detector (GE Discovery 670).

Methodik/Methods In 16 children with 37 I-123-mIBG SPECT/CT (range, 1-6 per patient; CZT: 12; NaI: 25), mean/maximum counts of normal organs (liver r/l, spleen, myocardium, blood pool, spine, gluteal muscles) and NB primary tumors or metastases were measured. SUV based on volume sensitivity for a homogenous cylindrical phantom were validated in a NEMA IEC body phantom. Data was reconstructed iteratively with attenuation correction, resolution recovery and with/without scatter correction (SC). SUV were compared with Mann-Whitney U (cameras) or Wilcoxon test (non-SC vs. SC). In 7 patients (22 exams), metabolic tumor volume (MTV)*SUVmax of primary tumors was correlated to MRI volume on serial scans (Pearson).

Ergebnisse/Results Both lesion SUVmax and SUVmean were similar for non-SC and SC data with NaI (each p>0.05) while only SUVmean were similar with CZT. Correlation of changes in MTV*SUVmax with changes in MRI volume was r=0.6 and r=0.59 for non-SC and SC, respectively. Partial volume corrected SUVmax did not considerably improve correlation (non-SC: r=0.64; SC: r=0.5). For each normal organ SUVmean were significantly higher for non-SC vs. SC data with both CZT and NaI (each p<0.05; except myocardium) while standard errors were lower. Organ SUVmean were similar with CZT and NaI for non-SC data (each p>0.1), but not for SC data (each p<0.05; except liver r/l, spleen and myocardium).

Schlussfolgerungen/Conclusions Quantification in I-123-mIBG SPECT/CT is feasible with CZT and NaI detectors, and therapy-associated changes in uptake of NB primary tumors correlated with MRI volume changes. Using specific sensitivity factors, both non-SC and SC data can be quantified. However, inter-subject variability of normal organ SUVmean was generally high, and non-SC data may be favorable.